药物性肝内胆管消失综合征的临床特征与转归

doi:10.3969/j.issn.1006-7795.2018.05.010

首都医科大学学报 ›› 2018, Vol. 39 ›› Issue (5): 675-679.doi: 10.3969/j.issn.1006-7795.2018.05.010

药物性肝内胆管消失综合征的临床特征与转归

耿文静¹, 刘晖², 范春蕾¹, 李磊¹, 董培玲¹, 丁惠国¹

1. 首都医科大学附属北京佑安医院肝病消化中心, 北京 100069;
2. 首都医科大学附属北京佑安医院临床病理中心, 北京 100069

收稿日期:2018-05-08 出版日期:2018-09-21 发布日期:2018-10-20
通讯作者: 丁惠国 E-mail:dinghuiguo@ccmu.edu.cn
基金资助:
北京市医院管理局扬帆计划（ZYLX201610），北京市医院管理局登峰计划（DFL20151602）。

Clinical features and prognosis of drug-induced vanishing bile duct syndrome

Geng Wenjing¹, Liu Hui², Fan Chunlei¹, Li Lei¹, Dong Peiling¹, Ding Huiguo¹

1. Department of Hepatology and Gastroenterology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China;
2. Department of Clinical Pathology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Received:2018-05-08 Online:2018-09-21 Published:2018-10-20
Supported by:
This study was supported by Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding(ZYLX201610), Beijing Municipal Administration of Hospitals' Ascent Plan (DFL20151602).

摘要/Abstract

摘要： 目的分析药物性肝损伤（drug-induced liver injury，DILI）伴胆管消失（vanishing bile duct syndrome，VBDS）患者的临床特征及转归。方法 2010年1月至2016年12月首都医科大学附属北京佑安医院临床诊断为DILI患者1 010例，其中267例肝脏穿刺，病理符合VBDS患者19例，在无胆管损伤DILI患者中采用数字表法随机抽取54例作为对照。比较两组患者的临床资料及转归。结果 VBDS占7.12%（19/267），73.68%（14/19）临床表现为胆汁淤积，26.32%（5/19）患者无黄疸。与无VBDS组相比，大部分VBDS患者进展为慢性肝损伤（88.2%vs 35.2%）。涉及药物包括性激素2例（10.5%），非甾体抗炎药3例（16%），免疫调节剂3例（16%），抗生素3例（16%），中草药4例（21%），染发剂1例（5%），质子泵抑制剂1例（5%），抗精神药2例（10.5%）。VBDS患者与无VBDS患者比较，总胆固醇（cholesterol，CHOL）［（8.4±3.9） mmol/L vs（4.4±1.5） mmol/L］、碱性磷酸酶（alkaline phosphatase，ALP）［（613.6±544.4） U/L vs（151.8±70.4） U/L］、谷氨酰转肽酶（glutamyl transpeptidase，GGT）［（631.2±472.8） U/L vs（228.7±174.4） U/L］均升高，差异均有统计学意义（P<0.05）。结论大部分VBDS患者临床表现胆汁淤积，VBDS可能是慢性DILI患者的病理基础，预后较差。

关键词: 药物性肝损伤, 胆管消失综合征, 预后

Abstract: Objective To analyze the clinical features and outcomes of the drug-induced liver injury (DILI) patients with vanishing bile duct syndrome (VBDS). Methods A total of 1010 patients with DILI were diagnosed clinically from January 2010 to December 2016. Of which, 267 patients underwent liver biopsy, 19 patients were diagnosed DILI with VBDS by histology. At the same time, 54 patients without VBDS were randomly enrolled as a control. The clinical data and outcomes of the two groups of patients were compared. Results In this study, VBDS accounted for 7.12% (19/267). Of DILI patients with VBDS, 73.68% (14/19) patients had cholestasis, 26.32% (5/19) had no jaundice. The majority of VBDS patients were developed to chronic liver injury(88.2% vs 35.2%)compared to those without VBDS. Those drugs included sex hormones drugs(n=2), non-steroidal anti-inflammatory drugs (n=3), immunomodulators drugs (n=3), antibiotics(n=3), herbal products(n=4), hair dye (n=1),proton pump inhibitor (n=1), and antipsychotics(n=1). VBDS patients had significantly higher than those without VBDS serum cholesterol(CHOL)[(8.4±3.9) vs (4.4±1.5)mmol/L], alkaline phosphatase (ALP)[(613.6±544.4)U/L vs (151.8±70.4)U/L], and glutamyl transpeptidase(GGT)[(631.2±472.8)U/L vs (228.7±174.4)U/L] (P<0.05). Conclusion Most DILI patients with VBDS have cholestasis. VBDS may be the pathological basis of patients' development to chronic DILI with poor prognosis.

Key words: drug induced liver injury, vanishing bile duct syndrome, prognosis

中图分类号:

R575

耿文静, 刘晖, 范春蕾, 李磊, 董培玲, 丁惠国. 药物性肝内胆管消失综合征的临床特征与转归[J]. 首都医科大学学报, 2018, 39(5): 675-679.

Geng Wenjing, Liu Hui, Fan Chunlei, Li Lei, Dong Peiling, Ding Huiguo. Clinical features and prognosis of drug-induced vanishing bile duct syndrome[J]. Journal of Capital Medical University, 2018, 39(5): 675-679.

参考文献

[1] Beger R D, Bhattacharyya S, Yang X, et al. Translational biomarkers of acetaminophen-induced acute liver injury[J]. Arch Toxicol, 2015, 89(9):1497-1522.
[2] Chalasani N, Bonkovsky H L, Fontana R, et al. Features and outcomes of 889 patients with drug-induced liver injury:the DILIN prospective study[J]. Gastroenterology, 2015, 148(7):1340-1352.
[3] Visentin M, Lenggenhager D, Gai Z, et al. Drug-induced bile duct injury[J].Biochim Biophys Acta, 2017, 1864(4 Pt B):1498-1506.
[4] Björnsson E S, Jonasson J G. Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome:rare but has severe consequences[J]. Hepatology, 2017, 65(4):1091-1093.
[5] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 中华肝脏病杂志, 2015, 23(11):810-820.
[6] Ludwig J, Wiesner R H, Batts K P, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation[J]. Hepatology, 1987, 7(3):476-483.
[7] Ortega-Alonso A, Andrade R J. Chronic liver injury induced by drugs and toxins[J]. J Dig Dis, 2018,Epub ahead of print.
[8] Bénichou C. Criteria of drug-induced liver disorders:report of an international consensus meeting[J]. J Hepatol, 1990, 11(2):272-276.
[9] Bakhit M, Mccarty T R, Park S, et al. Vanishing bile duct syndrome in hodgkin's lymphoma:a case report and literature review[J]. World J Gastroenterol, 2017, 23(2):366-372.
[10] 叶立红, 王翀奎, 张海丛,等. 药物相关性胆管消失综合征的临床病理特征[J].中华肝脏病杂志, 2017, 25(4):317-320.
[11] Bonkovsky H L, Kleiner D E, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements[J]. Hepatology, 2017, 65(4):1267-1277.
[12] 孙玥, 赵新颜, 贾继东. 药物相关性胆管消失综合征诊断及治疗进展[J]. 肝脏, 2014,19(5):360-362.
[13] Kawasaki Y, Matsubara K, Hashimoto K, et al. Nonsteroidal anti-inflammatory drug-induced vanishing bile duct syndrome treated with plasmapheresis[J]. J Pediatr Gastroenterol Nutr, 2013, 57(5):e30.
[14] Bhayana H, Appasani S, Thapa B R, et al. Lamotrigine-induced vanishing bile duct syndrome in a child[J]. J Pediatr Gastroenterol Nutr, 2012, 55(6):e147-148.
[15] Orman E S, Conjeevaram H S, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury[J]. Clin Gastroenterol Hepatol, 2011, 9(6):517-523.e3.
[16] Geubel A P, Sempoux C L. Drug and toxin-induced bile duct disorders[J]. J Gastroenterol Hepatol, 2000, 15(11):1232-1238.
[17] Capra F, Nicolini N, Morana G, et al. Vanishing bile duct syndrome and inflammatory pseudotumor associated with a case of anabolic steroid abuse[J]. Digest Dis Sci, 2005, 50(8):1535-1537.
[18] Chatterjee S, Annaert P. Drug-induced cholestasis:mechanisms, models, and markers[J]. Curr Drug Metab, 2018, Epub ahead of print.
[19] Paula, Oppenheimer, Christopher, et al. Vanishing bile duct syndrome in human immunodeficiency virus infected adults:A report of two cases[J]. World J Gastroenterol, 2013, 19(1):115-121.
[20] Juricic D, Hrstic I, Radic D, et al. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man[J]. Basic Clin Pharmacol Toxicol, 2010, 106(1):62-65.
[21] Smith L A, Ignacio J R, Winesett M P, et al. Vanishing bile duct syndrome:amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid[J]. J Pediatr Gastroenterol Nutr, 2005, 41(4):469-73.
[22] Jakab S S, West A B, Meighan D M, et al. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome[J]. World J Gastroenterol, 2007, 13(45):6087-6089.

药物性肝内胆管消失综合征的临床特征与转归

Clinical features and prognosis of drug-induced vanishing bile duct syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王荣荣, 田俊萍. 急性冠脉综合征患者血清钙与心血管预后的关系[J]. 首都医科大学学报, 2023, 44(1): 154-160.
[2]	贾静, 陈文明, 李燕郴. 多发性骨髓瘤伴中枢侵犯临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(1): 161-166.
[3]	于天宇, 姜世敏, 高红梅, 邹古明, 李文歌. 糖尿病肾病慢性肾脏病4期患者肾脏临床及病理因素与预后的关系[J]. 首都医科大学学报, 2022, 43(5): 707-712.
[4]	郭康林, 程一春, 葛树旺, 徐钢. IgA肾病国际风险预测工具在中国人群中的预测效果评价[J]. 首都医科大学学报, 2022, 43(5): 713-719.
[5]	谷强, 余孝君, 张津. 高龄与中低龄老年轻型缺血性脑卒中临床特点及预后分析[J]. 首都医科大学学报, 2022, 43(3): 474-479.
[6]	周巧云, 黄晓武, 夏恩兰, 赵玉婷, 黄睿. 子宫动脉栓塞后宫腔粘连的生殖结局分析[J]. 首都医科大学学报, 2022, 43(3): 490-494.
[7]	苗祖霈, 张迎花, 肖克令, 司瑾, 张浩宇, 李静. 肥胖程度对急性ST段抬高型心肌梗死患者预后的影响[J]. 首都医科大学学报, 2022, 43(2): 192-198.
[8]	孙婧, 史幼梧, 贾军, 杨颖, 孙志伟, 杜丰, 余靖, 肖艳洁, 张晓东. 血液炎症相关指标在晚期胰腺癌中的预后价值[J]. 首都医科大学学报, 2022, 43(2): 299-304.
[9]	刘洋, 吴玉梅, 何玥, 樊蓓, 王雁, 赵辉, 王明. ⅠB期子宫颈癌国际妇产科联盟2018新分期的合理性验证及评估[J]. 首都医科大学学报, 2021, 42(6): 1026-1032.
[10]	王莉, 张国军. 血清神经元特异性烯醇化酶与外伤性脑损伤患者及临床特征的关系[J]. 首都医科大学学报, 2021, 42(5): 715-720.
[11]	来璇, 张爱华. 代谢综合征对慢性肾脏病患者生存预后的影响[J]. 首都医科大学学报, 2021, 42(4): 609-614.
[12]	王欣, 张俊璇, 高健, 石汉平. 免疫营养改善肿瘤患者预后[J]. 首都医科大学学报, 2020, 41(6): 1019-1024.
[13]	刘军, 曹庆飞, 叶雄俊, 陈伟男, 赵海岳, 佟明, 王银银, 黄晓波, 常智杰. CREPT在肾癌组织中的表达及其与预后的关系[J]. 首都医科大学学报, 2020, 41(4): 552-557.
[14]	吴西抗, 王跃, 贺慧颖. 上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系[J]. 首都医科大学学报, 2020, 41(3): 354-359.
[15]	曹迪, 李先亮, 张荟, 贺强. 影响肝门部胆管癌术后远期预后的因素[J]. 首都医科大学学报, 2020, 41(3): 439-443.